



Prof. Gordana Dragović Lukić, MD, PhD

Department of Pharmacology, Clinical Pharmacology and Toxicology; School of Medicine; University of Belgrade, Belgrade, Serbia

Dr Subotica 1/III; 11129 Belgrade; Serbia

e-mail: gozza@beotel.net

EDUCATION:

2008. Doctor of Medical Science (PhD), School of Medicine; University of Belgrade, Belgrade

2003. Spec. in Clinical Pharmacology, School of Medicine; University of Belgrade, Belgrade

2002. Master of Science (MSc), School of Medicine; University of Belgrade, Belgrade, Serbia

1998. State License for Medical Doctors (MD), Ministry of Health and Welfare; Belgrade, Serbia

1997. Medical Doctor (MD) degree, School of Medicine; University of Belgrade, Belgrade, Serbia

1991-1997. School of Medicine; University of Belgrade, Belgrade, Serbia

ADDITIONAL EDUCATION:

2005. University of Washington, Center for AIDS and Sexually Transmitted Diseases & World Health Organization (WHO) Collaborative Center for AIDS and STD, University of Washington, Seattle, Washington, USA.

2004. Research training and research methods, Erasmus Winter Programme 2004; Netherlands Institute for Health and Science (NIHES), Erasmus University; Rotterdam, The Netherlands.

2002. Research training in clinical research, Erasmus Summer Programme 2002; Netherlands Institute for Health and Science (NIHES), Erasmus University; Rotterdam, The Netherlands.

RESEARCH EXPERIENCE:

2004, 2005, 2006, 2007, 2015. Visiting Research Fellow; Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK.

2003, 2006, 2007. Visiting Research Fellow at the University of Liverpool, Liverpool HIV Pharmacology Group of the Department of Pharmacology and Therapeutics, Liverpool, UK.

2013. Visiting Research Fellow; Clinica della malattie infettive e tropicali, University of Modena, Modena, Italy.

PARTICIPANT IN NATIONAL RESEARCH PROJECTS:

2003-2005. Project N° 1483 Ministry of science and technology of the Republic of Serbia.

2008-2010. Project N° 145015 Ministry of science and technology of the Republic of Serbia.

2011-2016. Project N° 175024 Ministry of science and technology of the Republic of Serbia.

PARTICIPANT IN INTERNATIONAL RESEARCH PROJECTS:

2011-2013 (FP6, NAET): Project number: LSHP-CT-2006-037570

2014-2016 IATOS project (leader)

AWARDS:

2003. International AIDS Society (IAS): International award for young scientists - 2nd IAS Conference on HIV Pathogenesis and Treatment, 13th-16th July 2003, Paris, France.

2004. HIV Research Trust: International award for original research for the scientists under 35 years from developing countries (Prof. Bob Sauhami, MD, PhD: "One of the four highest scoring applicants according to the reviewers assessment"), 7th International Congress on Drug Therapy in HIV Infection, 14th-18th November 2004, Glasgow, United Kingdom.

MEMBERSHIPS:

1. Serbian Pharmacological society (**SFD**)
2. Serbian Medical Society (**SLD**)
3. European Association for Clinical Pharmacology and Therapeutics (**EACPT**)
4. International Union of Pharmacology (**IUPHAR**)
5. European AIDS Clinical Society (**EACS**)
6. International Union of Pharmacology (**IUPHAR**)

SKILLS:

Teaching experience in Serbian and English language.

Good Clinical Practice Training/GCP licence.

Experience in clinical trials.

Published papers in national and international journals.

Published chapters in the national books.

OTHER:

- **Co-chair of the 13th European AIDS Conference/EACS, 12th-15th October 2011, Belgrade, Serbia; Member of the Scientific Committee of the 13th European AIDS Conference/EACS**
- **2008.-2014. Member of the Country Coordinating Mechanism (CCM); Government of Serbia-Global fund for HIV/AIDS and TB.**
- **2011.-2013. Member of the oversight committee under the Country Coordinating Mechanism, CCM; Global Fund, Government of Serbia-Global fund for HIV/AIDS and TB.**
- **2010.-2015. Member of the National expert team for TB/HIV under the Country Coordinating Mechanism, CCM; Global Fund, Government of Serbia-Global fund for HIV/AIDS and TB.**

IMPORTANT PUBLICATIONS:

1. **Dragović G**, Jevtović Đ. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. *Antivir Chem Chemother* 2003; 14(5):281-84. **IF=1.767, M=22**
2. **Dragović G**, Milić N, Jevtović Đ. Incidence of acute pancreatitis and nucleoside reverse transcriptase inhibitors usage. *Int J STD AIDS* 2005; 16(6):427-29. **IF=1.121, M23**
3. Jevtović Đ, Salemović D, Ranin J, Pešić I, **Dragović G**, Žerjav S, Đurković Đaković O. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART. *Biomed Pharmacother* 2008; 62(1):21-25. **IF=2.198, M22**
4. **Dragović G**, Smith C, Jevtović Đ, Johnson M, Salemović D, Ranin J, Youle M. Comparison of Nucleoside Reverse Transcriptase Inhibitor use as part of the first-line therapy in a Serbian and UK HIV Clinic. *HIV Clin Trials* 2009; 10(5):306-13. **IF=1.626, M22**

5. Jevtović Đ, **Dragović G**, Salemović D, Ranin J, Đurković-Đaković O. The metabolic syndrome, an epidemic among HIV-infected patients on HAART. *Biomed Pharmacother* 2009; 63(5):337-42. **IF=2.238, M22**
6. Miković Ž, Karadžov N, Jovanović I, Milić V, Tomović B, Egić A, **Dragović G**. Developmental delay associated with normal thyroidal function and long-term amiodarone therapy during fetal and neonatal life. *Biomed Pharmacother* 2010; 64(6):396-68. **IF=2.208, M22**
7. **Dragović G**, Grbović L, Jevtović Đ, Andjelić S, Vasić B, Lukić R. Safety of antiretrovirals in pregnancy. *Vojnosanit Pregl* 2011; 68(11):967-74. **IF=0.179, M23**
8. Vasić B, Andjelić S, Lukić R, Jevtović Dj, Grbović L, Vasiljević T, **Dragović G**. Postexposure prophylaxis against hepatitis B, hepatitis C and human immunodeficiency virus infection in healthcare workers. *Vojnosanit Pregl* 2011; 68(11):975-78. **IF=0.179, M23**
9. Jevtović Đ, **Dragović G**. The role of nucleoside reverse transcriptase inhibitor usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients. *Biomed Pharmacother*. 2012; 66(4):308-11. **IF=2.026, M23**
10. **Dragović G**, Grbović L, Jevtović Đ. Pharmacogenetics of antiretroviral drugs. *Vojnosanit Pregl* 2012; 69 (12):1091-96. **IF=0.210, M23**
11. Jevtović Đ, **Dragović G**, Salemović D, Ranin J, Kušić J, Marinković J, Đuraković- Đaković O. Treatment outcome of HAART-treated patients in resource-limited setting: The Belgrade Cohort Study. *Biomed Pharmacother*. 2014; 68(3):391-95. **IF=2.108, M23**.
12. Olagunju A, Siccardi M, Amara A, Jevtović D, Kušić J, Owen A, **Dragović G**. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. *Ther Drug Monit*. 2014; 36(6):734-38. **IF=1.926, M22**.
13. **Dragović G**, Salemović D, Ranin J, Nikolić J, Kušić J, Jevtović D. Clinical and immunologic outcomes of HAART-treated HIV-infected women in resource constrain settings: the Belgrade Study. *Women Health* 2014; 54(1):35-47. **IF=1.194, M21**.
14. **Dragovic G**. The role of adipokines in HIV lipodystrophy. *Germs*. 2015; 5(3):64.
15. Begovac J, **Dragovic G**, Viskovic K, Kusic J, Mihanovic Perovic M, Lukas D, Jevtovic Dj. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. *Croat Med J*. 2015; 56:14-23.
16. Kusic J, Mladenovic M, Dimitrijevic B, Aleksic B, Zec S, Jevtovic Dj, **Dragovic G**. Treatment outcomes of first-line antiretroviral therapy in HIV-1 positive patients in Serbia. *J Virus Erad*, 2016. (in press).
17. **Dragovic G**, Smith C, Jevtovic Dj, Dimitrijevic B, Kusic J, Youle M, Johnson M. Choice of first-line antiretroviral therapy regimen and treatment outcomes of HIV in middle income compare to high income country: A cohort study. *BMC Infect Dis*, 2016, (in press).